Alberta Transplant Institute and Canadian Donation and Transplantation Research Program, Edmonton, Canada; Dept. of Pediatrics, University of Alberta, Edmonton, Alberta, Canada
Auto-generated profile, based on publicly available information
Kesheng Tao
Alberta Transplant Institute and Canadian Donation and Transplantation Research Program, Edmonton, Canada; Dept. of Pediatrics, University of Alberta, Edmonton, Alberta, Canada
ABO antibodies pose barriers in transplantation but remain poorly studied. We investigated anti-A natural antibodies (nAbs) and induced antibodies (iAbs) in wild-type (WT), CD19KO, and CD22KO mice in the context of MHC-syngeneic or MHC-allogeneic stimulation by ABO-A blood cell membranes (BCM) from A-transgenic mice, or xenogeneic human (Hu-A) BCM. CD19KO mice failed to produce anti-A nAbs and iAbs. Syngeneic A-transgenic-BCM failed to stimulate anti-A iAbs in WT mice, in contrast to allogeneic A-transgenic-BCM and xenogeneic Hu-A-BCM. Hu-A-BCM failed to stimulate anti-A iAbs in CD4-T-cell-depleted or CD4KO mice, reversed with CD4-T-cell reconstitution. While anti-A nAbs were absent in estrogen-receptor-α-deficient mice, anti-A iAbs were easily stimulated. Anti-A nAbs were higher in CD22KO than WT mice, pubertal females producing higher levels than males. Anti-A iAbs were stimulated in CD22KO mice by syngeneic A-transgenic-BCM or by Hu-A-BCM after CD4-T-cell depletion. We conclude that anti-A nAbs and iAbs are produced by B1a-cells. In WT mice, stimulation of anti-A iAbs requires exposure to non-self A-antigen together with foreign proteins and is T-cell-dependent. Without CD22-mediated inhibition, anti-A iAb stimulation does not require foreign protein and is T-cell-independent. Anti-A iAbs are estrogen-independent whereas anti-A nAbs are estrogen-dependent and could be elicited by estrogen in males.
A strategy for augmenting multivalent glycoconjugates with a serum-protein recognition element extends half-life in vivo and maintains engagement with lectin receptors.
5 January 2023 in American Journal of Transplantation
Heart transplant and recipient survival are limited by immune cell-mediated injury of the graft vasculature. We examined the role of the phosphoinositide 3-kinase-β (PI3Kβ) isoform in endothelial cells (EC) during coronary vascular immune injury and repair in mice. In minor histocompatibility-antigen mismatched allogeneic heart grafts, a robust immune response was mounted to each wild-type, PI3Kβ inhibitor-treated, or endothelial-selective PI3Kβ knockout (ECβKO) graft transplanted to wild-type recipients. However, microvascular EC loss and progressive occlusive vasculopathy only developed in control, but not PI3Kβ-inactivated hearts. We observed a delay in inflammatory cell infiltration of the ECβKO grafts, particularly in the coronary arteries. Surprisingly, this was accompanied by an impaired display of proinflammatory chemokine and adhesion molecules by the ECβKO ECs. In vitro, tumor necrosis factor α-stimulated endothelial ICAM1 and VCAM1 expression was blocked by PI3Kβ inhibition or RNA interference. Selective PI3Kβ inhibition also blocked tumor necrosis factor α-stimulated degradation of inhibitor of nuclear factor kappa Bα and nuclear translocation of nuclear factor kappa B p65 in EC. These data identify PI3Kβ as a therapeutic target to reduce vascular inflammation and injury.
1 April 2017 in The Journal of Heart and Lung Transplantation